SAN DIEGO, Jan. 22, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) ("Cidara") today commenced the previously announced rights offering to raise gross proceeds of approximately $30.0 million (the "Rights Offering"). Under the terms of the Rights Offering, the holders, as of 5:00 p.m., New York time, on January 21, 2020, of Cidara's common stock and Series X convertible preferred stock, and Cidara's warrants issued on May 21, 2018, are entitled to purchase up to 11,952,191…

Rights Offering will be available to all stockholders and 2018 warrant holders of record on January 21, 2020 $30.0 million to be raised, fully backstopped SAN DIEGO, Jan. 10, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) ("Cidara") today announced its intent to raise $30.0 million through a fully backstopped rights offering. Under the terms of the rights offering, investors as of January 21, 2020 in Cidara's common stock and preferred stock, as well as the…

ASH presentation will include new preclinical data on rezafungin for prevention of PneumocystisSAN DIEGO, Dec. 03, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will present a poster at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, which takes place Dec 7-10, 2019, in Orlando, Fl, and will deliver an oral presentation at the 39th Interdisciplinary Meeting on Anti-Infective Chemotherapy, which…

Employee feedback places Cidara among top small companies in the areaSAN DIEGO, Nov. 18, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has been named a Top Workplace by The San Diego Union-Tribune for the third consecutive year. Cidara was the top life sciences company and only biotech included in the small company category in the San Diego Metro Area. "It is a great…

SAN DIEGO, Nov. 07, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended September 30, 2019 and provided an update on its corporate activities and product pipeline. "The last several months represent a truly transformative period for Cidara. Our partnership with Mundipharma validated the significant commercial potential of rezafungin and provides financial and other resources that enable us to continue…

SAN DIEGO, Nov. 05, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will host a Key Opinion Leader (KOL) meeting on its rezafungin and Cloudbreak programs on November 14 in New York City for institutional investors, sell-side analysts, and business development professionals. The meeting will feature presentations from Key Opinion Leaders, Neil J. Clancy, M.D. (University of Pittsburgh), Kieren Marr, M.D. (Johns Hopkins University…

SAN DIEGO, Oct. 03, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will present three posters at the Infectious Diseases Society of America (IDSA) IDWeek 2019, which takes place October 2-6, 2019, in Washington, D.C., and four posters, including a late-breaking poster, at the 9th Trends in Medical Mycology (TIMM), which takes place October 11-14, 2019, in Nice, France. The presentations at IDWeek will…

SAN DIEGO, Sept. 16, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Paul Daruwala, chief operating officer, and James Levine, chief financial officer of Cidara are scheduled to participate in 1x1 meetings with investors at the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies, which takes place on September 23, 2019, and that Jeffrey Stein, Ph.D., president and chief executive officer of…

Collaboration combines strengths to develop and commercialize life-saving antifungal treatment and prophylaxis, an area of high unmet medical need Mundipharma acquires exclusive rights to develop and commercialize rezafungin in all markets outside of the United States and Japan, which will be retained by Cidara Cidara to receive upfront payment of $30 million and equity investment of $9 million, co-development funding, development milestones and tiered royalty stream Total transaction value could exceed $568 million Cidara to…

SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that five abstracts, including one late-breaker, highlighting data from its Cloudbreak® antiviral program have been accepted for presentation at the Options X for the Control of Influenza conference taking place August 28-September 1 in Singapore. "Cidara's presentations at this important global conference highlight our commitment to addressing an unmet medical need for better and more effective approaches…